Research Article

Clinical observational study of conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent ovarian cancer

Published: April 22, 2015
Genet. Mol. Res. 14 (2) : 3833-3842 DOI: https://doi.org/10.4238/2015.April.22.12
Cite this Article:
(2015). Clinical observational study of conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent ovarian cancer. Genet. Mol. Res. 14(2): gmr4906. https://doi.org/10.4238/2015.April.22.12
1,154 views

Abstract

This retrospective study aimed to observe the cura­tive effect and adverse reactions of three-dimensional conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent epithelial ovarian carcinoma. The chemoradiotherapy group (N = 22) received 15 mv X-rays with 1.8 to 2.0 Gy/f/d radiation, 5 times per week. The total dose was 45 to 65 Gy; the median dose was 52.5 Gy. Topotecan chemotherapy (2.0 mg/m2) was administered after the first week of radiotherapy on days 1, 8, and 15; it was repeated every 28 days. The only che­motherapy group (N = 20) received topotecan chemotherapy (4.0 mg/m2) in the first week, and the dose was administered on days 1, 8, and 15; it was repeated every 28 days. The median follow-up times were 18.5 months (2 to 37.7) and 10.8 months (1.5 to 29.6) in the chemoradiotherapy and in the only chemotherapy groups, respectively. The total response rates were 42.1% (8/19) and 11.1% (2/18), respectively. The clinical benefit rates were 68.4% (13/19) and 22.2% (4/18), respectively, with significant difference (P 0.05). As three-dimensional conformal radiotherapy combined with topotecan che­motherapy had good curative effect on platinum-resistant recurrent epithelial ovarian cancer, with mild adverse reactions, this tech­nique can be used as a remedial measure.

This retrospective study aimed to observe the cura­tive effect and adverse reactions of three-dimensional conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent epithelial ovarian carcinoma. The chemoradiotherapy group (N = 22) received 15 mv X-rays with 1.8 to 2.0 Gy/f/d radiation, 5 times per week. The total dose was 45 to 65 Gy; the median dose was 52.5 Gy. Topotecan chemotherapy (2.0 mg/m2) was administered after the first week of radiotherapy on days 1, 8, and 15; it was repeated every 28 days. The only che­motherapy group (N = 20) received topotecan chemotherapy (4.0 mg/m2) in the first week, and the dose was administered on days 1, 8, and 15; it was repeated every 28 days. The median follow-up times were 18.5 months (2 to 37.7) and 10.8 months (1.5 to 29.6) in the chemoradiotherapy and in the only chemotherapy groups, respectively. The total response rates were 42.1% (8/19) and 11.1% (2/18), respectively. The clinical benefit rates were 68.4% (13/19) and 22.2% (4/18), respectively, with significant difference (P 0.05). As three-dimensional conformal radiotherapy combined with topotecan che­motherapy had good curative effect on platinum-resistant recurrent epithelial ovarian cancer, with mild adverse reactions, this tech­nique can be used as a remedial measure.